Further time-course experiments need to be carried out in rat and human cohorts, to determine whether or not circulating CRT is, as we propose, a new robust surrogate biomarker of demyelinating disease and a possible ‘chaperokine’ in MS. This evidence concerns the gene CALR and demyelinating disease.